Fragaria indica stem, leaf, and root extract was used to assess the antimicrobial activity against bla-TEM beta-lactamase producing Shigella flexneri, Salmonella typhi, and Escherichia coli. Ethanolic extracts of F. indica leaves exhibited a maximum zone of inhibition of 20 ± 1.2 mm (p < 0.001), 18 ± 1.4 mm (p < 0.001), and 16 ± 1.5 mm (p < 0.001) against E. coli, S. flexneri, and S. typhi, respectively. To identify different compounds, the bioactive ethanolic leaf extracts were further processed for HPLC, GC-MS, ADMET, and docking analysis. In the ethanolic leaf extract, 19 phenolic compounds were identified in HPLC analysis. Three phenolic compounds, including Isorhamnetin-3-rutinoside, 5, 7-Dihydroxy-4’ -methoxyflavone, and Luteolin, were for the first time reported in F. indica. In GC-MS analysis, sixteen compounds were identified. From the literature search, among the identified compounds, AlphaHimachalene, 1,3-Diphenyl-1-((trimethylsilyl)oxy)-1(Z)-heptene, 1H-Benzocycloheptene, Bicyclo[5.2.0] nonane, cis-1,1,3,4-Tetramethylcyclopentane, Bicyclo[2.2.2]octane-cis-2,3-diyl Carbonate, BetaHimachalene and 2-methylene-4,8,8-trimethyl-4-vinyl were reported for the first time in F. indica. Two compounds, including Alpha-Himachalene and Bicyclo[2.2.2]octane-cis-2,3-diyl carbonate, having good water solubility, drug likeness, and medicinal characteristics, were selected for docking analysis. Docking of Alpha-Himachalene and Bicyclo[2.2.2]octane-cis-2,3-diyl carbonate showed interaction with Pro-26, Phe-22, and Ala-23 residues of bacterial bla-TEM beta-lactamase. Similarly, Bicyclo[2.2.2] octane-cis-2,3-diyl carbonate interacts with amino acid residues of Ala-235 and Ser-233 of bla-TEM beta-lactamase. Further studies will help to characterize the anti-infective compounds against bla-TEM producing foodborne bacterial pathogens.

Plants are alternative source of natural medicines due to secondary active metabolites. Fagonia cretica extracts and Gradient High-Pressure Liquid Chromatography fractionations were checked against multidrug-resistant gastrointestinal pathogens including, Salmonella typhi, Escherichia coli and Shigella flexneri. ESI-MS/MS analysis of bioactive HPLC fractions was performed to elucidate antibacterial compounds. F. cretica extracts exhibited potential antibacterial activity. Twenty-four (24) HPLC fractions were obtained from methanol, ethanol and aqueous extracts of F. cretica. Eighteen (18) fractions showed antibacterial activity, while no activity was observed by the remaining six (6) fractions. HPLC fractions, F1 (25g ± 0.20 mm) and F2 (15f ± 0.12 mm) of aqueous extract exhibited activity against multidrug resistant GI pathogens. Gallic acid, quinic acid, cyclo-l-leu-l-pro, vidalenolone, liquirtigenin, rosmarinic acid and cerebronic acid were identified in F1 fraction of aqueous extract, while succinic acid, cyclo (l-Leul-Pro) and liquirtigenin were identified in F2 fraction of aqueous extract through ESI-MS/MS analysis. F. cretica extracts and HPLC fractions showed potential activity against MDR GI pathogens. Vidalenolone, Cyclo-1-leu-1-pro and Cerebronic acid are first time reported in F. cretica. Further characterization of bioactive compounds from F. cretica may be helpful to elucidate antibacterial therapeutic molecules.